Why BioNTech Shares Are Falling

BioNTech SE BNTX is trading significantly lower Monday as vaccine names pull back after gaining in late November amid omicron concerns.

The World Health Organization is now saying that the omicron variant has been detected in more than 40 countries since it was first reported by South African health authorities. However, reports from South Africa suggest that hospitalization rates have not increased alarmingly.

U.S. health officials said Sunday that although the omicron variant is rapidly spreading throughout the country, early indications suggest it may be less dangerous than the delta variant.

Dr. Anthony Fauci made it clear that scientists still need more information before drawing conclusions, but provided some optimism about the severity of the new coronavirus strain.

"Thus far, it does not look like there’s a great degree of severity to it," Fauci said. “But we have really got to be careful before we make any determinations that it is less severe or it really doesn’t cause any severe illness, comparable to delta.”

See Also: Pfizer/BioNTech's COVID-19 Shot Receives Emergency Use Nod In Australia For Kids Aged 5-11 Years

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19.

BNTX Price Action: BioNTech has traded as high as $464 and as low as $80.55 over a 52-week period.

The stock was down 13.80% at $296.51 at time of publication.

Photo: x3 from Pixabay.